Literature DB >> 8195959

Clinical variations of trilateral retinoblastoma: a report of 13 cases.

P De Potter1, C L Shields, J A Shields.   

Abstract

Of 440 consecutive children with retinoblastoma whom we treated between April 1972 and April 1992, 13 (3%) developed a midline intracranial neoplasm. Four of these 13 patients had bilateral familial retinoblastoma, 7 had bilateral sporadic retinoblastoma, and 1 patient had unilateral familial retinoblastoma. The twin brother of the latter patient developed pinealoblastoma without retinoblastoma. In this series, the incidence of trilateral retinoblastoma was 8% of all bilateral familial retinoblastoma and 5% of all bilateral sporadic retinoblastoma. The retinoblastoma was diagnosed at a mean age of 4.5 months and the midline intracranial tumor was diagnosed at a mean age of 23 months. The mean time interval between the diagnosis of retinoblastoma and the intracranial tumor was 22 months (range, 0 to 48 months). Seven patients (55%) were asymptomatic and their intracranial neoplasm was found on routine brain-imaging studies. The primary intracranial neoplasm had a pineal location in 10 cases and parasellar location in three cases. Despite aggressive combined treatment, 12 patients (92%) have died at a mean interval of 11 months after the diagnosis of intracranial malignancy. The mean survival of patients with midline intracranial neoplasm who were asymptomatic was significantly longer than that of symptomatic patients (P = .05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8195959     DOI: 10.3928/0191-3913-19940101-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  18 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Imaging in the trilateral retinoblastoma syndrome.

Authors:  L J Bagley; R W Hurst; R A Zimmerman; J A Shields; C L Shields; P De Potter
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

3.  High-dose chemotherapy followed by autologous and allogeneic peripheral blood stem cell transplantation for recurrent disseminated trilateral retinoblastoma.

Authors:  Toshihisa Tsuruta; Yasuo Aihara; Hitoshi Kanno; Chikako Kiyotani; Katsuya Maebayashi; Masako Sakauchi; Makiko Osawa; Hisaichi Fujii; Osami Kubo; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2011-03-19       Impact factor: 1.475

4.  Expression of multidrug resistance proteins in retinoblastoma.

Authors:  Swati Shukla; Arpna Srivastava; Sunil Kumar; Usha Singh; Sandeep Goswami; Bhavna Chawla; Mandeep Singh Bajaj; Seema Kashyap; Jasbir Kaur
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

5.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

6.  Bilateral retinoblastoma: clinical presentation, management and treatment.

Authors:  Francesco Pichi; Andrea Lembo; Mariacarla De Luca; Theodora Hadjistilianou; Paolo Nucci
Journal:  Int Ophthalmol       Date:  2013-01-01       Impact factor: 2.031

7.  Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy.

Authors:  Karen D Wright; Ibrahim Qaddoumi; Zoltan Patay; Amar Gajjar; Matthew W Wilson; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

8.  Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma.

Authors:  Aubin Balmer; Francis Munier
Journal:  Clin Ophthalmol       Date:  2007-12

Review 9.  Trilateral retinoblastoma: an institutional experience and review of the literature.

Authors:  Elzbieta Jurkiewicz; Iwona Pakuła-Kościesza; Olga Rutynowska; Katarzyna Nowak
Journal:  Childs Nerv Syst       Date:  2009-07-31       Impact factor: 1.475

10.  CRX is a diagnostic marker of retinal and pineal lineage tumors.

Authors:  Sandro Santagata; Cecile L Maire; Ahmed Idbaih; Lars Geffers; Mick Correll; Kristina Holton; John Quackenbush; Keith L Ligon
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.